p53 in life and death

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 435-440

  Shimamura, Akiko ^a   Fisher, David E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; CELL CYCLE; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029872783     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Linzer, D. I., and Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17: 43-52, 1979.
2. Lane, D. P., and Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature (Lond.), 278: 261-263, 1979.
3. Lane, D. P., and Benchimol, S. p53: oncogene or anti-oncogene. Genes & Dev., 4: 1-8, 1990.
4. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
5. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827-830, 1992.
6. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
7. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
8. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
9. Mack, D. H., Vartikar, J., Pipas, J. M., and Laimins, L. A. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (Lond.), 363: 281-283, 1993.
10. Seto, E., Usheva, A., Zambetti, G. P., and Al, E. Wild-type p53 binds to the TATA-binding protein and repressed transcription. Proc. Natl. Acad. Sci. USA, 89: 12028-12032, 1992.
11. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC), 265: 346-355, 1994.
12. Friend, S. p53: a glimpse at the puppet behind the shadow play. Science (Washington DC), 265: 334-335, 1994.
13. Aguilar, F., Harris, C C., Sun, T., Hollstein, M., and Cerutti, P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science (Washington DC), 264: 1317-1319, 1994.
14. Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., and Gronengorn, A. M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science (Washington DC), 265: 386-391, 1994.
15. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-45, 1993.
16. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. 1. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-po53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
17. Donehower, L., Harvey, M., Slagle, B., McArthur, M., Montgomery, C., Butel, J., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
18. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990
19. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A , Bischoff, F. Z., Tainsky, M. A., and Friend, S. H. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science (Washington DC), 250: 1233-1238, 1990.
20. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994.
21. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigeneisis. Cell, 61: 759-767, 1990.
22. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
23. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
24. Kuerbitz, S., Plunkett, B., Walsh, W., and Kastan, M. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
25. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tisty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
26. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
27. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
28. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
29. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
30. Pines, J. p21 inhibits cyclin shock. Nature (Lond.), 569: 520-521, 1994.
31. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
32. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., and Elledge, S. J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
33. Skapek, S. X., Rhee, J., Spicer, D. B., and Lassar, A. B. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science (Washington DC), 207: 1022-1024, 1995.
34. Michieli, O., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of Waf1/Cip1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
35. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes & Dev., 9: 935-944, 1995.
36. Smith, M. L., Chen, I-T., Zhan, Q., Bae, I., Chen, C-Y., Gilmer, T., Kastan, M. B., O'Connor, P M., and Fornace, A. J. Interaction of the p53-regulated protein GADD 45 with proliferating cell nuclear antigen. Science (Washington DC), 266: 1376-1380, 1994.
37. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA, 91: 2230-2234, 1994.
38. Fan, S., Smith, M. K., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
39. 2 delay. Cancer Res., 55: 1643-1648, 1995.
40. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
41. Clarke, A. R., Purdie, C. A., Harrison, D. J , Morris, R. G., Bird, C. C , Hooper, M. L., and Al, E. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
42. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
43. Lowe, S. W., Ruley, H. E , Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
44. Yonish-Rouach, E., Resnitsky, D., Lotem, J., Sachs, K., Kim-Chi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
45. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA, 90: 5742-5746, 1993.
46. Lowe, L. W., Bodis, B., McCarthy, A., Remington, L. H., Ruley, E., Fisher, D., Housman, D. E., and Jacks, T. p53 can determine the efficacy of cancer therapy in vitro. Science (Washington DC), 266: 807-810, 1994.
47. Fan, S., El-Deiry, W. S., Bae, L. Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Magrath, I., Kohn, K. W , and O'Connor, P. M. p53 mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents Cancer Res., 54: 5824-5830, 1994.
48. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
49. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
50. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
51. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum,R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
52. Hermeking, H., and Eick, D. Mediadon of c-Myc-induced apoptosis by p53. Science (Washington DC), 265: 2091-2093, 1994.
53. Wagner, A. J., Kokontis, J. M., and Hay, N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes & Dev., 8: 2817-2830, 1994.
54. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
55. Caelles, C., Helmberg, A., and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (Lond.), 379: 220-223, 1994.
56. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80: 293-299, 1995.